. 2020 Nov 4;15(11):e0241071. doi: 10.1371/journal.pone.0241071

Table 2. HIV drug resistance by sex, age, and locality type, South Africa, 2017.

Variable	n	Resistance %# (95% CI)	p value	NNRTI only resistance %# (95% CI)	p value	Dual NNRTI & NRTI resistance %# (95% CI)	p value
Sex
Male	252	29.4 (22.5–37.4)	0.473	19.6 (13.5–27.7)	0.772	9.7 (5.8–15.7)	0.202
Female	445	25.8 (19.8–32.8)	0.473	18.3 (13.2–24.8)	0.772	6.3 (4.2–9.5)	0.202
Age
0–14 years (Total)	26	33.7 (17.6–54.7)		17.7 (7.2–37.4)		14.9 (5.3–35.2)
Male	12	35.8 (14.6–64.6)	0.823	^**	0.749	^**	0.461
Female	14	31.5 (11.1–62.8)	0.823	^**	0.749	^**	0.461
15–24 years (Total)	98	30.5 (18.7–45.5)		22.1 (12.6–35.9)		5.7 (1.7–16.8)
Male	25	48.7 (26.7–71.2)	0.067	36.7 (17.8–60.7)	0.063	^**	^**
Female	73	22.6 (11.4–39.7)	0.067	15.8 (7.4–30.7)	0.063	^**	^**
25+ years (Total)	573	26.6 (21.7–32.2)		18.4(14.0–23.8)		7.9 (5.4–11.4)
Male	215	27.1 (19.6–36.1)	0.89	18.0 (11.5–27.0)	0.88	9.1(5.1–15.8)	0.45
Female	358	26.3 (19.6–34.1)	0.89	18.8 (13.1–26.3)	0.88	6.9 (4.3–10.8)	0.45
15–49 years (Total)	568	27.5 (22.5–33.2)		19.2 (14.8–24.4)		7.8(5.3–11.3)
Male	207	28.8 (21.4–37.6)	0.676	19.7 (13.2–28.2)	0.857	9.1 (5.1–15.9)	0.392
Female	361	26.4 (19.7–34.4)	0.676	18.7 (13.0–26.2)	0.857	6.6 (4.1–10.4)	0.392
50+years (Total)	103	24.1 (14.8–36.7)		17.0 (8.9–30.0)		5.7 (2.5–12.8)
Male	33	34.8 (15.1–61.5)	0.191	21.8 (5.8–56.0)	0.562	^**	^**
Female	70	19.8 (11.7–31.4)	0.191	15.1 (8.2–26.2)	0.562	^**	^**
Locality type
Urban	388	29.5 (23.5–36.4)	0.077	21.0 (15.6–27.6)	0.138	7.6 (4.8–11.9)	0.792
Rural informal (tribal areas) & rural formal (farms)	309	23.1 (17.4–30.1)	0.077	14.6 (9.8–21.1)	0.138	(5.2–12.9)	0.792

# Weighted percentages.

** Sample was too small for the respective disaggregation and comparisons.

NNRTI- non-nucleoside reverse transcriptase inhibitors; NRTI- nucleoside reverse transcriptase inhibitors.